Back to News
Market Impact: 0.55

Mars' $36 billion Kellanova deal gets US antitrust approval as EU opens investigation

KPEPKHCMDLZHSYGISKR
M&A & RestructuringAntitrust & CompetitionRegulation & LegislationConsumer Demand & RetailInflation
Mars' $36 billion Kellanova deal gets US antitrust approval as EU opens investigation

Mars' $36 billion acquisition of Kellanova has secured U.S. antitrust clearance from the Federal Trade Commission, which found no anti-competitive concerns. However, the European Union has launched a full-scale investigation into the deal, citing fears it could lead to price hikes for consumers by boosting Mars' negotiating power with retailers due to strong brand positions in multiple EU markets. This divergence means the transaction, expected to close in late 2025, faces significant hurdles in Europe, potentially requiring divestitures or risking a block.

Analysis

The $36 billion acquisition of Kellanova by Mars now faces a significant transatlantic regulatory divergence, creating material uncertainty for the deal's closure. While U.S. antitrust authorities, including the Federal Trade Commission, have granted early clearance by concluding the merger does not harm competition, their European Union counterparts have initiated a full-scale investigation. The EU's primary concern, reflecting the article's overall mildly negative sentiment, is that the combination of "must-have" brands like M&Ms and Pringles will grant the new entity excessive negotiating power over retailers, leading to higher consumer prices amidst persistent food inflation. This EU probe, with a decision deadline of October 31, introduces the risk of forced divestitures or an outright block, directly contradicting the U.S. assessment and jeopardizing the stated late 2025 completion target. The negative sentiment specifically attached to Kellanova (K) underscores that this heightened deal risk now overshadows the positive U.S. regulatory outcome.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo